No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Eitan Medical Announces Updated Distribution Arrangement

Editor: What To Know

  • “We look forward to the successful transition of the business back to Eitan Medical and ICU Medical's ability to focus on our Best in KLAS Plum™ platform and ICU Medical MedNet™ software to improve the safety, efficiency, and operating effectiveness of our customers' IV therapy practices.
  • We are appreciative and thankful to Dan Woolson and the entire ICU Medical team for serving as a valuable strategic partner to Eitan Medical, and for working collaboratively to provide advanced infusion therapy solutions these past few years,” said Igal Shany, CEO of Eitan Medical.
  • Eitan Medical announced today that all current Sapphire™ Infusion System customers of ICU Medical in France, UK and the US will be serviced by Eitan Medical, the manufacturer of the Sapphire™ Infusion System.

Eitan Medical announced today that all current Sapphire™ Infusion System customers of ICU Medical in France, UK and the US will be serviced by Eitan Medical, the manufacturer of the Sapphire™ Infusion System.

Eitan Medical will now become the exclusive supplier and service provider for its own Sapphire™ Infusion System, including the provision of administration sets, accessories, spare and technical parts and repair and preventative maintenance services.

Eitan Medical has further agreed to be a distributor for administration sets manufactured by ICU Medical for the Sapphire™ Infusion System, further bolstering Eitan Medical’s current administration set supply around the world.

“This transition marks the completion of a successful and beneficial partnership between Eitan Medical and ICU Medical. We are appreciative and thankful to Dan Woolson and the entire ICU Medical team for serving as a valuable strategic partner to Eitan Medical, and for working collaboratively to provide advanced infusion therapy solutions these past few years,” said Igal Shany, CEO of Eitan Medical. “Eitan Medical strives to enhance its commitment to patient care, comfort and safety through innovation and exceptional customer experience. We continue to illustrate our patient-centricity through continued development of our flagship Sapphire™ infusion pump, a proven and well-known solution within the healthcare ecosystem, capable of answering the evolving needs of patients in need via intuitive and patient-minded performance.”

“We look forward to the successful transition of the business back to Eitan Medical and ICU Medical’s ability to focus on our Best in KLAS Plum™ platform and ICU Medical MedNet™ software to improve the safety, efficiency, and operating effectiveness of our customers’ IV therapy practices.” said Dan Woolson, Corporate Vice President and GM of ICU Medical.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy